INOTREM
Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210712005071/en/
As part of this program, Inotrem receives additional 45 million euros in public funding under the "Capacity Building" Call for Expression of Interest, operated on behalf of the French government by Bpifrance, the French national investment bank, as part of the Programme d’investissements d’avenir (PIA) and the France Recovery Plan, bringing French state support for the project to a total of 52,5 million euros. This public funding will support Inotrem’s clinical program including the phase 2/3 study “ESSENTIAL” which aims to demonstrate the efficacy and safety of nangibotide in treating patients in respiratory distress with severe forms of COVID-19.
The primary endpoint is evaluation of the impact of nangibotide on the progression of disease in patients receiving ventilatory support due to COVID-19 as well as on the severity of the respiratory failure, duration of mechanical ventilation, length of stay in intensive care and mortality. In “ESSENTIAL”, a Phase 2/3 clinical program, up to 730 patients will be enrolled initially in France and Belgium and, possibly in other European countries. Pre-defined interim analyses will be conducted by an independent Data Monitoring Board to test futility and to allow for the study design to be adapted as necessary. “ESSNTIAL” is the continuation of a 60 patients phase 2a evaluating the safety and efficacy of nangibotide in patients suffering from severe COVID-19. In July 2020, the CoviTREM-1 consortium, which includes the Nancy and Limoges university hospitals and Inotrem, obtained public funding of 7,5 million euros under the “PSPC-COVID” call for projects, operated on behalf of the French government by Bpifrance
New pre-clinical studies with nangibotide have demonstrated that the administration of nangibotide in murine models infected with SARS-CoV-2 was associated with a decrease in inflammatory mediators and an improvement of clinical signs, in particular respiratory function, and survival. Inotrem also confirmed in 3 different and independent cohorts that sTREM-1, a marker of the activation of the TREM-1 biological pathway, is associated with both severity and mortality in critically ill COVID-19 patients.
Leveraging the results of these preclinical studies and the implications for the role of the TREM-1 pathway in COVID-19, Inotrem has filed additional patents to cover nangibotide use in severe forms of COVID-19 as well as the use of sTREM-1 as a biomarker and companion diagnostic. This significantly strengthens Inotrem’s already broad patent estate.
Jean-Jacques Garaud, Executive Vice-President, Head of Scientific and Medical Affairs and Inotrem’s co-founder said :“We are eager to pursue the development of nangibotide in these severe forms of COVID-19. Nangibotide is a TREM-1 inhibitor which has already demonstrated a trend towards efficacy in septic shock patients and has the potential to modulate the dysregulated immune response in critically ill COVID-19 patients. With this large clinical study, we can demonstrate efficacy for nangibotide in a further indication with the goals of reducing the duration of hospitalization and mortality.”
Sven Zimmerman, CEO of Inotrem, also declared : “The size of the financial support awarded to us as part of the French government’s initiative against COVID-19 is a testimony to the relevance of targeting the TREM-1 pathway with nangibotide in these severely ill patients. We are delighted by the confidence placed in our technology and our team. Everyone at Inotrem is fully committed to deliver on this ambitious program alongside nangibotide’s ongoing Phase 2b trial in septic shock patients.”
About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
About TREM-1 pathway
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.
About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock.
About ESSENTIAL study:
The Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients with ventiLatory support, is a randomized, double-blind, placebo-controlled confirmatory study with adaptive features that will be performed in Europe. This is a pivotal study and it is expected that based on its results, nangibotide could be registered in this indication. The first part of the study (i.e.: 60 patients) has been already finalized and assessed by an independent data monitoring committee with excellent safety results. The study will recruit up to 730 patients in up to 40 sites. Several interim and futility analyses are foreseen as part of the adaptive design of the study.
About Bpifrance
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra-financial services (training, consultancy.). to help entrepreneurs meet their challenges (innovation, export…).
For more information, please visit: www.bpifrance.fr
and presse.bpifrance.fr
Follow us on Twitter: @Bpifrance - @BpifrancePresse
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005071/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cessna Citation Ascend Achieves FAA Certification, Bringing Advanced Features to the Most Popular Midsize Business Jet Family6.11.2025 14:15:00 CET | Press release
The Cessna Citation Ascend, designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone Wednesday, November 5, as the Federal Aviation Administration (FAA) awarded type certification for the aircraft, with entry into service expected later this year. The aircraft boasts an entirely new cockpit, improved performance and luxurious flat floor cabin, giving customers versatility and flexibility to accomplish their mission. Two flight test articles completed more than 1,000 flight hours and numerous certification tests to achieve FAA certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106032431/en/ Cessna Citation Ascend achieves FAA certification, bringing advanced features to the most popular midsize business jet family (Photo credit: Textron Aviation). “The Citation Ascend’s successful flight test program reflects our teams’ expertise in obtaining FAA certifica
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 14:00:00 CET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 14:00:00 CET | Press release
Over 10 billion single-use boxes replaced with reusable packaging in global fresh grocery supply chains IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 14:00:00 CET | Press release
LIBELULATM trial completed enrollment of Central Precocious Puberty (CPP) patients in North and South America, advancing the path for Debio 4326, a triptorelin injectable 12-month extended-release formulation Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argenti
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 13:00:00 CET | Press release
As the U.K. Market Fuels Growing Interest from Domestic and International Activists, Investors Have Adapted their Approach to Gain Access to Boardrooms in Germany and Italy The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what loo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom